Brian T Hill

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Pulmonary involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma is a specific pathologic finding independent of inflammatory infiltration
    Brian T Hill
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 53:589-95. 2012
  2. ncbi Acute myeloid leukemia: when to transplant in first complete remission
    Brian T Hill
    Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Curr Hematol Malig Rep 5:101-8. 2010
  3. ncbi Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Biol Blood Marrow Transplant 16:1738-46. 2010
  4. ncbi The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Br J Haematol 152:561-9. 2011
  5. ncbi Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 52:986-93. 2011

Detail Information

Publications5

  1. ncbi Pulmonary involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma is a specific pathologic finding independent of inflammatory infiltration
    Brian T Hill
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 53:589-95. 2012
    ..Moreover, LPI by CLL is not a bystander effect secondary to acute inflammation, but instead represents a distinct pathologic process in a subset of patients...
  2. ncbi Acute myeloid leukemia: when to transplant in first complete remission
    Brian T Hill
    Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Curr Hematol Malig Rep 5:101-8. 2010
    ..Because of the expanded use of umbilical cord blood as a source of hematopoietic stem cells and the use of reduced-intensity conditioning regimens, allogeneic HSCT is an option for an increasing number of patients with AML...
  3. ncbi Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Biol Blood Marrow Transplant 16:1738-46. 2010
    ..NMA second transplants were associated with substantially less NRM and despite a higher incidence of relapse, significantly improved survival compared to MA second transplants...
  4. ncbi The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Br J Haematol 152:561-9. 2011
    ..After ASCT, surviving patients have significantly increased risk mortality rates relative to the general population and this excess risk persists over time...
  5. ncbi Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma
    Brian T Hill
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 52:986-93. 2011
    ..001). These findings suggest that alternative mobilizing strategies prior to ASCT are needed for patients with mantle cell lymphoma who have received hyper-CVAD...